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Rationale There is no consensus as to when treatment
for idiopathic pulmonary ﬁbrosis (IPF) should be initiated.
Some physicians prefer not to treat patients with
preserved lung volume.
Objective To investigate whether patients with IPF and
preserved lung volume receive the same beneﬁt from
nintedanib as patients with more impaired lung volume.
Methods Post hoc subgroup analyses of pooled data
from the two replicate phase III INPULSIS trials by
baseline FVC % predicted (≤90%, >90%).
Results At baseline, 274 patients had FVC >90%
predicted and 787 patients had FVC ≤90% predicted. In
patients treated with placebo, the adjusted annual rate
of decline in FVC was consistent between patients with
FVC >90% predicted and FVC ≤90% predicted
(−224.6 mL/year and −223.6 mL/year, respectively).
There was no statistically signiﬁcant difference between
these subgroups in the effect of nintedanib on annual
rate of decline in FVC, change from baseline in St
George’s Respiratory Questionnaire total score or time to
ﬁrst acute exacerbation. In patients with baseline FVC
>90% predicted and ≤90% predicted, respectively, the
adjusted annual rate of decline in FVC with nintedanib
was −91.5 mL/year (difference vs placebo: 133.1 mL/
year (95% CI 68.0 to 198.2)) and −121.5 mL/year
(difference vs placebo: 102.1 mL/year (95% CI 61.9 to
142.3)). Adverse events associated with nintedanib were
similar in both subgroups.
Conclusions Patients with IPF and preserved lung
volume (FVC >90% predicted) have the same rate of
FVC decline and receive the same beneﬁt from
nintedanib as patients with more impaired lung volume.
Trial registration number NCT01335464 and
NCT01335477.
INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a speciﬁc
form of interstitial pneumonia associated with
chronic dyspnoea and cough, and the progressive
loss of lung function.1 The clinical course of IPF is
variable and difﬁcult to predict, with some patients
progressing rapidly, others relatively slowly and
some experiencing acute deteriorations in respira-
tory function that are associated with high morbid-
ity and mortality.2 A decline in FVC reﬂects disease
progression in patients with IPF and is predictive of
mortality.3–6 Data from phase II–III trials in
patients with IPF and mild or moderate impairment
of lung function suggest that the decline in FVC in
patients receiving placebo is ∼200 mL/year.7–12
Nintedanib is an intracellular inhibitor of tyrosine
kinases13 that has been approved for the treatment
of IPF in several countries and regions including the
USA, EU, Canada and Japan. Nintedanib received a
conditional recommendation for use in the treat-
ment of IPF in the latest international clinical prac-
tice guideline.14 The efﬁcacy and safety of
nintedanib 150 mg twice daily in patients with IPF
were assessed in the two replicate, randomised,
placebo-controlled, 52-week, phase III INPULSIS
trials (NCT01335464 and NCT01335477).12 In
both INPULSIS trials, nintedanib signiﬁcantly
reduced the annual rate of decline in FVC (primary
endpoint). A beneﬁt of nintedanib versus placebo on
the key secondary endpoints of time to ﬁrst
investigator-reported acute exacerbation and change
from baseline in St George’s Respiratory
Questionnaire (SGRQ) total score over 52 weeks
was observed in INPULSIS-2, but not in
INPULSIS-1. The adverse events most frequently
associated with nintedanib were gastrointestinal
events, particularly diarrhoea.12
IPF is commonly described using the terms
‘mild’, ‘moderate’ and ‘severe’, or ‘early’ and
‘advanced’.15 However, there is no standard deﬁn-
ition for what constitutes ‘mild disease’ or ‘margin-
ally impaired lung function’ in patients with IPF
and no consensus regarding at which point therapy
should be initiated or stopped, particularly as no
treatment has been shown to provide signiﬁcant
Key messages
What is the key question?
▸ Do patients with idiopathic pulmonary ﬁbrosis
(IPF) and preserved lung volume receive the
same beneﬁt from nintedanib as patients with
more impaired lung volume?
What is the bottom line?
▸ Patients with IPF and FVC >90% predicted at
baseline have the same rate of FVC decline and
receive the same beneﬁt from nintedanib as
patients with more impaired lung volume.
Why read on?
▸ These data provide, for the ﬁrst time, evidence
in a signiﬁcant subgroup of patients with
preserved lung volume to support the concept
of offering early treatment to patients with IPF.
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symptomatic beneﬁt. Some national guidelines use thresholds of
FVC as a percentage of the predicted value (FVC % predicted)
to determine when pharmacological treatment for IPF should be
used16 but these are not based on scientiﬁc evidence.
The inclusion criteria used in the INPULSIS trials set no
upper limit on FVC % predicted. A recently published prespeci-
ﬁed subgroup analysis demonstrated a consistent effect of ninte-
danib in subgroups of patients with FVC ≤ and >70%
predicted at baseline.17 In this analysis, we investigated whether
patients with IPF and preserved lung volume (FVC > 90% pre-
dicted) received the same beneﬁt from nintedanib as patients
with greater impairment in lung volume. Some of these results
have been reported as an abstract.18
METHODS
The design of the INPULSIS trials has been described.12 The
clinical trial protocol was approved by an Independent Ethics
Committee and/or Institutional Review Board at all the partici-
pating centres. All patients provided written informed consent
prior to study entry. Eligible patients had been diagnosed with
IPF within the previous 5 years and had an FVC ≥50% pre-
dicted (no upper threshold), a diffusion capacity of the lung for
carbon monoxide (TLCO) 30% to 79% predicted and a FEV1/
FVC ratio ≥0.7. Patients were randomised to receive nintedanib
150 mg twice daily or placebo in a 3:2 ratio.
Post hoc analyses in subgroups of patients with baseline FVC
>90% versus ≤90% predicted were conducted using pooled
data from the two INPULSIS trials. Analyses were conducted in
patients who received ≥1 dose of study drug. Analyses were
conducted on the primary endpoint (annual rate of decline in
FVC) and the key secondary endpoints (time to ﬁrst
investigator-reported acute exacerbation and change from base-
line in SGRQ total score) by repeating the primary analysis
for each endpoint (described in ref. 12) in each subgroup.
The statistical model used for the primary analysis assumed that
missing data were missing at random; missing data were not
imputed. For the primary endpoint, the terms subgroup and an
interaction term treatment-by-time-by-subgroup were included
in the model. For the key secondary endpoints, the terms sub-
group and an interaction term treatment-by-subgroup were
included in the model.
Time to disease progression over 52 weeks, deﬁned as an
absolute decline in FVC ≥10% predicted or death, or an abso-
lute decline in FVC ≥5% predicted or death, was assessed using
a Cox’s regression model with the terms subgroup and an inter-
action term treatment-by-subgroup included. Safety was assessed
through clinical and laboratory evaluation and recording
adverse events with onset after the ﬁrst dose and up to 28 days
after the last dose of study drug. Adverse events were coded
using the Medical Dictionary for Regulatory Activities
(MedDRA), V.16.1. Safety analyses were descriptive.
RESULTS
Patients
A total of 274 (25.8%) patients had baseline FVC >90% pre-
dicted (166 treated with nintedanib, 108 treated with placebo)
and 787 (74.2%) patients had baseline FVC ≤90% predicted
(472 treated with nintedanib, 315 treated with placebo).
Baseline characteristics of patients in each subgroup are pre-
sented in table 1.
Compared with patients with FVC ≤90% predicted, patients
with FVC >90% predicted had a shorter time since diagnosis,
higher TLCO % predicted and lower SGRQ total score (indicat-
ing better health-related quality of life), and were more likely to
have centrilobular emphysema (based on high-resolution CT
scan) and to be female. Within each subgroup, baseline
characteristics were similar between the nintedanib and placebo
groups.
Table 1 Baseline characteristics by subgroup (mean±SD or n (%))
FVC >90% predicted FVC ≤90% predicted
Nintedanib (n=166) Placebo (n=108) Nintedanib (n=472) Placebo (n=315)
Age, years 68.2±8.0 67.5±7.6 66.1±8.1 66.8±8.0
Male 121 (72.9) 75 (69.4) 386 (81.8) 259 (82.2)
Race
White 87 (52.4) 61 (56.5) 273 (57.8) 187 (59.4)
Asian 54 (32.5) 37 (34.3) 140 (29.7) 91 (28.9)
Black 0 (0.0) 0 (0.0) 2 (0.4) 0 (0.0)
Missing* 25 (15.1) 10 (9.3) 57 (12.1) 37 (11.7)
Smoking status
Never smoked 45 (27.1) 33 (30.6) 129 (27.3) 89 (28.3)
Ex-smoker 110 (66.3) 66 (61.1) 325 (68.9) 217 (68.9)
Current smoker 11 (6.6) 9 (8.3) 18 (3.8) 9 (2.9)
Time since diagnosis, years 1.4±1.2 1.3±1.3 1.7±1.4 1.7±1.3
Centrilobular emphysema 77 (46.4) 53 (49.1) 177 (37.5) 113 (35.9)
FVC, mL 3306±821 3420±945 2505±610 2491±598
FVC, % predicted 103.1±11.0 103.9±12.4 71.5±10.7 70.8±10.6
FEV1/FVC ratio, % 79.2±6.0 78.7±5.6 82.5±5.5 82.7±5.8
Diffusion capacity of the lung for carbon monoxide, % predicted† 52.8±13.3 52.3±12.6 45.5±13.1 45.1±13.2
St George’s Respiratory Questionnaire total score‡ 32.2±18.5 31.3±15.2 42.0±18.7 42.4±18.7
Composite physiologic index§ 37.3±9.8 37.2±9.2 49.0±9.5 49.5±9.7
*In France, regulation did not permit the collection of data on race.
†n=314 for placebo in FVC ≤90% predicted subgroup.
‡n=160 for nintedanib and n=106 for placebo in FVC >90% predicted subgroup and n=464 for nintedanib and n=313 for placebo in FVC ≤90% predicted subgroup.
§n=314 for placebo in FVC ≤90% predicted subgroup.
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In the subgroup of patients with baseline FVC >90% pre-
dicted, 43 patients (25.9%) in the nintedanib group and 11
patients (10.2%) in the placebo group prematurely discontinued
trial medication. In the subgroup of patients with baseline FVC
≤90% predicted, 113 patients (23.9%) in the nintedanib group
and 69 patients (21.9%) in the placebo group prematurely dis-
continued trial medication.
In patients with baseline FVC >90% predicted, mean (SD)
duration of exposure was 10.1 (3.6) months and 11.3 (2.0)
months in the nintedanib and placebo groups, respectively. In
patients with baseline FVC ≤90% predicted, mean (SD) dur-
ation of exposure was 10.4 (3.3) months and 10.7 (3.0) months
in the nintedanib and placebo groups, respectively.
Annual rate of decline in FVC
In patients with baseline FVC >90% predicted, the adjusted
annual rate of decline in FVC was −91.5 mL/year in the ninte-
danib group and −224.6 mL/year in the placebo group (differ-
ence of 133.1 mL/year (95% CI 68.0 to 198.2)) (ﬁgure 1). In
patients with baseline FVC ≤90% predicted, the adjusted
annual rate of decline in FVC was −121.5 mL/year in the ninte-
danib group and −223.6 mL/year in the placebo group (differ-
ence of 102.1 mL/year (95% CI 61.9 to 142.3)) (ﬁgure 1). The
treatment-by-subgroup interaction p value was not signiﬁcant
(p=0.530), indicating that the treatment effect of nintedanib
was not different between the subgroups. The primary endpoint
results were supported by the observed changes from baseline in
FVC over time in each subgroup (see online supplementary
ﬁgure S1).
Disease progression
In patients with baseline FVC >90% predicted, the HR for time
to an absolute decline in FVC ≥10% predicted or death was 0.59
(95% CI 0.38 to 0.89) in favour of nintedanib (table 2; ﬁgure 2).
In patients with baseline FVC ≤90% predicted, the correspond-
ing HR was 0.61 (95% CI 0.48 to 0.78) in favour of nintedanib
(table 2; ﬁgure 2). The treatment-by-subgroup interaction p value
was not signiﬁcant (p=0.830), indicating that the treatment
effect of nintedanib was not different between the subgroups by
baseline FVC. In both subgroups, most patients who met this
endpoint did so based on absolute decline in FVC ≥10% pre-
dicted rather than death, but the proportion of patients who died
over 52 weeks was higher in patients with FVC ≤90% predicted
than >90% predicted at baseline (table 2).
In patients with baseline FVC >90% predicted, the HR for
time to an absolute decline in FVC ≥5% predicted or death
over 52 weeks was 0.67 (95% CI 0.50 to 0.90) in favour of nin-
tedanib; the proportion of patients who met this endpoint was
60.2% in the nintedanib group and 77.8% in the placebo
group. In patients with baseline FVC ≤90% predicted, the cor-
responding HR was 0.59 (95% CI 0.49 to 0.71) in favour of
nintedanib (ﬁgure 3); the proportion of patients who met this
endpoint was 48.7% in the nintedanib group and 69.5% in the
placebo group. The treatment-by-subgroup interaction p value
was not signiﬁcant (p=0.486), indicating that the treatment
effect of nintedanib was not different between the subgroups by
baseline FVC.
Acute exacerbations
In patients with baseline FVC >90% predicted, the HR for
time to ﬁrst acute exacerbation was 0.46 (95% CI 0.09 to 2.48)
in favour of nintedanib (ﬁgure 4); the proportion of patients
with ≥1 acute exacerbation was 1.8% in the nintedanib group
and 2.8% in the placebo group (three patients in each group).
In patients with baseline FVC ≤90% predicted, the HR for time
to ﬁrst acute exacerbation was 0.66 (95% CI 0.39 to 1.11) in
favour of nintedanib (ﬁgure 4); the proportion of patients with
≥1 acute exacerbation was 5.9% in the nintedanib group and
9.2% in the placebo group (28 and 29 patients, respectively).
The treatment-by-subgroup interaction p value was not
Figure 1 Adjusted annual rate (SE) of decline in FVC (mL/year) by
subgroup.
Table 2 Proportions of patients with disease progression over 52 weeks and HR for time to first event by subgroup
FVC >90% predicted FVC ≤90% predicted
Nintedanib (n=166) Placebo (n=108) Nintedanib (n=472) Placebo (n=315)
Absolute decline in FVC ≥10% predicted or death, n (%) 44 (26.5) 44 (40.7) 129 (27.3) 131 (41.6)
HR (95% CI) 0.59 (0.38 to 0.89) 0.61 (0.48 to 0.78)
Treatment-by-subgroup interaction p=0.8304
Criterion reached first, n (%)
Absolute decline in FVC ≥10% predicted 42 (25.3) 43 (39.8) 106 (22.5) 110 (34.9)
Death 2 (1.2) 1 (0.9) 23 (4.9) 21 (6.7)
Absolute decline in FVC ≥5% predicted or death, n (%) 100 (60.2) 84 (77.8) 230 (48.7) 219 (69.5)
HR (95% CI) 0.67 (0.50 to 0.90) 0.59 (0.49 to 0.71)
Treatment-by-subgroup interaction p=0.4862
Criterion reached first, n (%)
Absolute decline in FVC ≥5% predicted 99 (59.6) 83 (76.9) 218 (46.2) 209 (66.3)
Death 1 (0.6) 1 (0.9) 12 (2.5) 10 (3.2)
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signiﬁcant (p=0.956), indicating that the treatment effect of
nintedanib was not different between the subgroups.
SGRQ total score
In patients with baseline FVC >90% predicted, the adjusted
mean change from baseline in SGRQ total score at week 52 was
2.16 in the nintedanib group and 3.02 in the placebo group
(difference of −0.87 (95% CI −3.97 to 2.24)) (see online
supplementary ﬁgure S2). In patients with baseline FVC ≤90%
predicted, the adjusted mean change from baseline in SGRQ
total score at week 52 was 4.00 in the nintedanib group and
5.64 in the placebo group (difference of −1.65 (95% CI −3.60
to 0.31)) (see online supplementary ﬁgure S2). The
treatment-by-subgroup interaction p value was not signiﬁcant
(p=0.3382), indicating that the treatment effect of nintedanib
was not different between the subgroups.
Adverse events
A summary of adverse events is shown in online supplementary
table S1. The proportions of patients who had ≥1 adverse event
Figure 2 Time to absolute decline in FVC ≥10% predicted or death over 52 weeks by subgroup. HR was 0.59 (95% CI 0.38 to 0.89) in patients
with baseline FVC >90% predicted and 0.61 (95% CI 0.48 to 0.78) in patients with baseline FVC ≤90% predicted. Treatment-by-subgroup
interaction p=0.830.
Figure 3 Time to absolute decline in FVC ≥5% predicted or death over 52 weeks by subgroup. HR was 0.67 (95% CI 0.50 to 0.90) in patients
with baseline FVC >90% predicted and 0.59 (95% CI 0.49 to 0.71) in patients with baseline FVC ≤90% predicted. Treatment-by-subgroup
interaction p=0.486.
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or ≥1 serious adverse event were comparable between the ninte-
danib and placebo groups within each subgroup. A higher pro-
portion of patients had ≥1 serious adverse event in the
subgroup of patients with baseline FVC ≤90% predicted than
FVC >90% predicted. Adverse events led to premature discon-
tinuation of study drug in 21.7% of nintedanib-treated patients
with baseline FVC >90% predicted and 18.4% of patients with
baseline FVC ≤90% predicted, compared with 7.4% and 14.6%
of placebo-treated patients in these subgroups, respectively.
Diarrhoea was the most frequent adverse event in patients
treated with nintedanib, reported in 62.0% of patients with
baseline FVC >90% predicted and 62.5% of patients with base-
line FVC ≤90% predicted, compared with 15.7% and 19.4% of
placebo-treated patients in these subgroups, respectively.
Diarrhoea led to premature discontinuation of study drug in
4.2% of nintedanib-treated patients with baseline FVC >90%
predicted and 4.4% of patients with baseline FVC ≤90% pre-
dicted, compared with no and 0.3% of placebo-treated patients
in these subgroups, respectively.
DISCUSSION
Our data from the INPULSIS trials have shown for the ﬁrst time
that placebo-treated patients with a baseline FVC >90% pre-
dicted have the same rate of FVC decline over the following
year as patients with greater impairment in lung volume and the
same likelihood of disease progression deﬁned as an absolute
decline in FVC % predicted ≥10% or death. It is notable that
over 40% of placebo-treated patients with an FVC >90% pre-
dicted at baseline, a subgroup that represented over 25% of
patients recruited into the INPULSIS trials, reached this disease
progression endpoint after 1 year. Furthermore, over 75% of
placebo-treated patients with an FVC >90% predicted at base-
line had an absolute decline in FVC % predicted of ≥5% after
1 year, suggesting that fewer than one in four patients with pre-
served lung volume at baseline had stable FVC over the follow-
ing year. Treatment with nintedanib slowed the annual rate of
decline in FVC in patients with FVC >90% and ≤90% pre-
dicted to the same extent. These are the ﬁrst data to show the
efﬁcacy of an antiﬁbrotic drug in patients with FVC >90%
predicted.
Low or worsening FVC has been shown to be a risk factor
for acute exacerbations.19–21 In this analysis, the proportion of
patients who had ≥1 acute exacerbation over 52 weeks was
higher in placebo-treated patients with FVC ≤90% than >90%
predicted (9.2% vs 2.8%). Nintedanib appeared to have the
same treatment effect on acute exacerbations in both subgroups,
but the interpretation of these data is limited by the low
number of acute exacerbations in the subgroup with FVC
>90% predicted (six events in 274 patients). No difference was
observed between subgroups in the effect of nintedanib in
change in SGRQ total score, which was small in both sub-
groups, consistent with the overall patient population.
Data from the INSIGHTS-IPF registry of patients with IPF in
clinical practice in Germany showed that patients with less
severe impairment in FVC are less likely to be receiving treat-
ment.22 However, the earlier that patients with IPF receive treat-
ment, the more lung function remains to be preserved. Further,
the clinical course of IPF in an individual patient is unpredict-
able; patients’ pulmonary function may decline rapidly shortly
after presentation6 23 and acute exacerbations can occur at any
point.1 It should also be noted that patients with IPF whose
lung function appears to be almost normal based on FVC %
predicted may already have lost a substantial amount of func-
tional lung tissue. Given the method used to calculate FVC %
predicted,24 some individuals will have had an FVC % predicted
some way above 100% before developing IPF. The presence of
emphysema, a common comorbidity in patients with IPF,25 also
increases FVC, presumably by mitigating the impact of ﬁbrosis
on ventilatory physiology.26
Our data argue against a ‘watch and wait’ approach for the
treatment of IPF and support the importance of prompt diagno-
sis of IPF to enable patients to receive treatment to slow disease
progression as soon as possible.27 28 Data from the CAPACITY
and ASCEND trials of pirfenidone have also demonstrated a
consistent effect of treatment across subgroups of patients by
FVC % predicted (≤65, 65–80, >80%) at baseline, although
patients with FVC >90% predicted were not eligible for the
Figure 4 Time to ﬁrst acute exacerbation over 52 weeks by subgroup. HR was 0.46 (95% CI 0.09 to 2.48) in patients with baseline FVC >90%
predicted and 0.66 (95% CI 0.39 to 1.11) in patients with baseline FVC ≤90% predicted. Treatment-by-subgroup interaction p=0.956.
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ASCEND study.29 However, it should be noted that the sub-
group analyses of both the nintedanib and pirfenidone trials are
based on group averages and these subgroups likely included a
number of patients who had no FVC decline during the study
period that could be stabilised with therapy. Other limitations
include the short duration of treatment, considering that IPF is
a chronic disease that may require treatment for longer than
1 year, and premature discontinuation of study medication in
22% of patients, consistent with treatment discontinuations seen
in other clinical trials in patients with IPF with a treatment dur-
ation of similar length.11 30
A concern might be raised that commencing treatment with
nintedanib earlier in the course of IPF might increase the risk
that patients would become resistant to the effects of the drug.
However, to date, there is no experimental or clinical evidence
to suggest the development of resistance to nintedanib in
patients with IPF. Indeed, the speciﬁcity of nintedanib against
growth factor receptors involved in antiangiogenesis (ie, the
ﬁbroblast growth factor, platelet-derived growth factor and vas-
cular endothelial growth factor receptors),31 together with its
antiproliferative activity on ﬁbroblasts prone to secrete growth
factors,32 argues against potential for treatment resistance.33 An
interim analysis of INPULSIS-ON, the open-label extension of
the INPULSIS trials, has shown that the decline in FVC in
patients continuing nintedanib in INPULSIS-ON was similar to
the decline in FVC in patients treated with nintedanib in
INPULSIS, suggesting that the effect of nintedanib on slowing
disease progression is maintained for at least 3 years.34
In conclusion, in this analysis of pooled data from the
INPULSIS trials, the annual rate of decline in FVC was similar
in placebo-treated patients with preserved lung volume (FVC
>90% predicted) at baseline as in patients with greater impair-
ment in lung volume. Nintedanib slowed the decline in lung
function independent of the degree of FVC impairment at base-
line, with a similar adverse event proﬁle in both subgroups.
These ﬁndings support the concept of offering treatment to
patients with IPF and preserved lung volumes at the time of
diagnosis, until there are markers that predict individual disease
course.
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